ArticleCureus2026
Expression of p57 Immunostain in Complete and Partial Hydatidiform Moles.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHydatidiform mole (HM) is a gestational trophoblastic disease characterized by abnormal proliferation of trophoblastic tissue. Accurate subclassification into complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) is essential, as CHM carries a higher risk of persistent trophoblastic disease and choriocarcinoma. Histopathology alone may be inconclusive due to overlapping features and interobserver variability. p57 immunohistochemistry has emerged as a valuable ancillary tool in differentiating CHM from PHM. This study aimed to evaluate p57 expression across histopathologically diagnosed cases of HM and determine its usefulness as a diagnostic marker. MATERIALS AND
methodsA cross-sectional observational study was conducted on 57 cases diagnosed as complete, partial, or indeterminate HM from the Bangladesh Medical University (BMU) and private laboratories in Dhaka. All cases were re-evaluated based on defined histopathological criteria. p57 immunohistochemistry was performed in the Department of Pathology, BMU, and staining results were compared across diagnostic groups. Statistical analysis was performed using SPSS Statistics version 22.0 for Windows (IBM Corp., Armonk, NY, USA). A p value <0.05 was considered significant. Results: Of 57 cases, 36 were histologically diagnosed as CHM, 13 as PHM, and eight as indeterminate. Among CHM, 32 (88.9%) showed negative p57 expression, while four (11.1%) were positive. In PHM cases, nine (69.2%) showed positive expression, and four (30.8%) were negative. Among indeterminate cases, six showed negative expression, and two were positive. p57 expression demonstrated a statistically significant association with final diagnosis, leading to reclassification of cases to 42 CHM and 15 PHM.
conclusionp57 immunostaining significantly enhances diagnostic accuracy and reduces ambiguity in differentiating complete from partial HM. Incorporation of p57 evaluation alongside histopathology is recommended for reliable subclassification of HM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.